J.P. Morgan Notebook: Monday, January 13
This article was originally published in The Pink Sheet Daily
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the first full day of the 2014 J.P. Morgan health care conference, including chats with the CEOs of Elcelyx Therapeutics and Arecor, news from Juno Therapeutics and Galena Biopharma, and more.
You may also be interested in...
J.P. Morgan Notebook: Thursday, January 16
News and notes from the fourth and final day of the 2014 J.P. Morgan Healthcare Conference, including highlights from Furiex Pharmaceuticals’ late-stage pipeline, GSK’s latest DPU, newly public Intrexon, and angel-backed KemPharm.
Alnylam’s Comeback: RNAi Developer Partners With Sanofi/Genzyme
Sanofi will take a 12% stake in Alnylam for $700 million in a transformative deal that revalidates the biotech’s RNAi technology platform after the company lost important big pharma partners three years ago. The announcement Jan. 13 kicked off the opening of the JP Morgan Healthcare conference.
Proteus Biomedical Inc.
Proteus Biomedical Inc. is developing a suite of proprietary MEMS-based technologies for congestive heart failure. It is staking its first claim in the fast-growing cardiac resynchronization therapy market.